A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1

By Sawka C.A.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 211-215

Springer Publishing Company

Access to resources Recommend Favorite

Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

By Nabholtz J.M.   Bonneterre J.   Buzdar A.   Robertson J.F.R.   Thurlimann B.   for the Arimidex Writing Committee on behalf of the Investigators  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1684-1689

Elsevier

Access to resources Recommend Favorite

Adjuvant endocrine therapy in premenopausal women with breast cancer

By González Martín Antonio   Cruz Susana   Márquez Raúl  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-09 ,pp. : 43-47

Springer Publishing Company

Access to resources Recommend Favorite

Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis

By Chi Feng  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 111-122

Springer Publishing Company

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite